WooGene B&G Valuation

Is A018620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A018620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A018620 (₩953) is trading below our estimate of fair value (₩3243.52)

Significantly Below Fair Value: A018620 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A018620?

Key metric: As A018620 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A018620. This is calculated by dividing A018620's market cap by their current revenue.
What is A018620's PS Ratio?
PS Ratio	0.5x
Sales	₩59.96b
Market Cap	₩27.39b

A018620 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	14.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A018620's PS Ratio compare to its peers?

The above table shows the PS ratio for A018620 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
A034940 ChoA Pharmaceutical	0.5x	n/a	₩29.7b
A179530 ADBiotech	2.5x	n/a	₩24.8b
A200780 BCWORLD PHARM	0.5x	n/a	₩38.1b
A080720 Union Korea Pharm	0.2x	n/a	₩15.4b
A018620 WooGene B&G	0.5x	n/a	₩27.4b

Price-To-Sales vs Peers: A018620 is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does A018620's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$159.05m
A096760 JW Holdings	0.2x	n/a	US$151.76m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$93.30m
A000230 Ildong Holdings	0.1x	n/a	US$57.08m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A018620 is good value based on its Price-To-Sales Ratio (0.5x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A018620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A018620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A018620's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩521.4b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩20,550.00

1.5%

-31.5%

Medy-Tox

₩869.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,900.00

0.5%

-41.1%

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%